Private Trust Co. NA Has $212,000 Position in Humana Inc. (NYSE:HUM)

Private Trust Co. NA decreased its position in shares of Humana Inc. (NYSE:HUM) by 5.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 668 shares of the insurance provider’s stock after selling 38 shares during the period. Private Trust Co. NA’s holdings in Humana were worth $212,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in HUM. CarsonAllaria Wealth Management Ltd. boosted its holdings in shares of Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares in the last quarter. Creative Financial Designs Inc. ADV boosted its stake in Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after buying an additional 61 shares in the last quarter. Atwood & Palmer Inc. acquired a new stake in Humana in the third quarter valued at about $29,000. Hantz Financial Services Inc. bought a new position in Humana in the second quarter valued at about $35,000. Finally, Family Firm Inc. acquired a new position in Humana during the second quarter worth about $37,000. 92.38% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

HUM has been the topic of several research reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $395.00 price target on shares of Humana in a report on Tuesday, October 1st. Barclays upped their price target on shares of Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Jefferies Financial Group downgraded Humana from a “buy” rating to a “hold” rating and cut their price objective for the company from $519.00 to $253.00 in a report on Monday, October 7th. Royal Bank of Canada lowered their target price on Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a research note on Thursday, October 3rd. Twenty analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $315.86.

Humana Stock Up 0.4 %

Shares of Humana stock opened at $296.68 on Friday. The stock’s 50-day moving average is $275.60 and its 200 day moving average is $329.77. Humana Inc. has a one year low of $213.31 and a one year high of $526.47. The firm has a market cap of $35.72 billion, a price-to-earnings ratio of 26.28, a PEG ratio of 2.40 and a beta of 0.52. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities research analysts anticipate that Humana Inc. will post 15.86 EPS for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.19%. Humana’s dividend payout ratio is currently 31.36%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.